idelalisib: Clinical Trials

27 trials of idelalisib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

12 terminated, 11 completed, 2 withdrawn, 1 active not recruiting. 27 Phase 2, 4 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 227Terminated 12, Completed 11, Withdrawn 2, Active not recruiting 1, Recruiting 1
Phase 14Terminated 3, Completed 1

Follow idelalisib: new trials by email Literature Review of idelalisib trials Research Report on idelalisib

Trials (filtered) newest first · largest first

All 27 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 2 Study of CAL101 in Patients With Idiopathic Pulmonary Fibrosis
CAL101, Placebo - Idiopathic Pulmonary Fibrosis
Phase 2Active not recruitingCalluna Pharma AS1502025-06-202026-04-27
Study to Investigate Outcome of Individualized Treatment in Patients With Metastatic Colorectal Cancer
Alectinib, Cetuximab, Crizotinib - Metastatic Colorectal Cancer
Phase 2RecruitingOslo University Hospital402022-09-272023-02-21
Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma
Loncastuximab Tesirine, Idelalisib - Relapsed Follicular Lymphoma, Refractory Follicular Lymphoma
Phase 2TerminatedADC Therapeutics S.A.62021-11-042023-10-23
Idelalisib+Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma
Idelalisib, Obinutuzumab - Follicular Lymphoma
Phase 2TerminatedFondazione Italiana Linfomi - ETS52019-10-182024-11-21
REALIB-LLA-2017: Idelalisib in Patients With Acute Lymphoblastic Leukemia
Idelalisib - Acute Lymphoblastic Leukemia
Phase 1 / Phase 2TerminatedPETHEMA Foundation62018-07-012021-09-05
1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation
Zydelig - Non Hodgkin Lymphoma, Follicular Lymphoma
Phase 2CompletedUniversity of Maryland, Baltimore172017-10-232025-06-27
Pembrolizumab + Idelalisib for Lung Cancer Study
Pembrolizumab, Idelalisib - Non Small Cell Lung Cancer, Metastasis
Phase 1 / Phase 2TerminatedAsha Nayak42017-09-262024-02-28
Trial of Idelalisib in Patients With Relapsed Diffuse Large B-cell Lymphoma
Idelalisib - Diffuse Large B Cell Lymphoma
Phase 2CompletedNordic Lymphoma Group362017-07-072021-10-13
Efficacity of Idelalisib and Obinutuzumab in Patient With Relapsed Refractory Waldenstrom's Macroglobulinemia
Obinutuzumab, Idelalisib - Waldenstrom Macroglobulinemia
Phase 2CompletedFrench Innovative Leukemia Organisation502017-03-072023-08-29
Study to Evaluate the Safety and Efficacy of the Combination of Tirabrutinib and Idelalisib With and Without Obinutuzumab in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)
Tirabrutinib, Idelalisib, Obinutuzumab - Chronic Lymphocytic Leukemia
Phase 2CompletedGilead Sciences352016-12-132022-01-21
Study to Evaluate Safety and Preliminary Efficacy of Tafasitamab With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi
Tafasitamab, Idelalisib, Venetoclax - Leukemia, Lymphocytic, Chronic, B-Cell, Chronic Lymphocytic Leukemia
Phase 2CompletedMorphoSys AG242016-11-012021-12-20
Ibrutinib or Idelalisib in Treating Patients With Persistent or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma After Donor Stem Cell Transplant
Ibrutinib, Idelalisib - Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
Phase 2WithdrawnFred Hutchinson Cancer Center2016-03-012017-09-27
Idelalisib for Immunoglobulin M (IgM)-Associated Primary (AL) Amyloidosis
Idelalisib - Amyloidosis
Phase 2TerminatedJohn Mark Sloan12016-01-012017-09-21
Study of Phosphatidylinositol-3-kinase (PI3K) Inhibitor Idelalisib (GS-1101) in Waldenström Macroglobulinemia
GS-1101 - Waldenstrom's Macroglobulinemia
Phase 2TerminatedDana-Farber Cancer Institute52015-10-012017-01-11
Idelalisib in Combination With Rituximab for Previously Untreated Follicular Lymphoma and Small Lymphocytic Lymphoma
Idelalisib, Rituximab - Follicular Lymphoma, Small Lymphocytic Lymphoma
Phase 2TerminatedGilead Sciences102015-09-142019-05-14
Sequential Regimen of Bendamustine-Debulking Followed by CAL-101 and GA101-Induction and -Maintenance in CLL (CLL2-BCG)
Bendamustine, GA101, CAL-101 - Chronic Lymphocytic Leucemia
Phase 2CompletedGerman CLL Study Group482015-05-282024-05-09
Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas
Ibrutinib, Idelalisib, Laboratory Biomarker Analysis - Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Chronic Lymphocytic Leukemia
Phase 2CompletedMayo Clinic652015-02-192026-06-24
Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion
Idelalisib, Rituximab - B-cell Chronic Lymphocytic Leukemia (CLL) With 17p Deletion
Phase 2TerminatedGilead Sciences1022014-08-062018-11-19
A Study of Idelalisib (GS1101, CAL101) + Ofatumumab in Previously Untreated CLL/SLL
Idelalisib, Ofatumumab - Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Phase 2CompletedDana-Farber Cancer Institute272014-06-012026-03-17
Entospletinib in Combination With Idelalisib in Adults With Relapsed or Refractory Hematologic Malignancies
Entospletinib, Idelalisib - Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
Phase 2TerminatedGilead Sciences662013-06-202020-06-02

Showing 20 of 27. Sign in to see all of them.

Conditions studied

Leukemia, Lymphocytic, Chronic, B-Cell (14)  ·  Lymphoma, Follicular (7)  ·  Waldenstrom Macroglobulinemia (6)  ·  Lymphoma, Non-Hodgkin (5)  ·  Lymphoma, B-Cell, Marginal Zone (4)  ·  Lymphoma (2)  ·  Lymphoma, B-Cell (2)  ·  Lymphoma, Large B-Cell, Diffuse (2)  ·  Precursor Cell Lymphoblastic Leukemia-Lymphoma (2)  ·  Amyloidosis (1)  ·  Carcinoma, Non-Small-Cell Lung (1)  ·  Colorectal Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Idiopathic Pulmonary Fibrosis (1)  ·  Leukemia (1)

Sponsors

Gilead Sciences (10)  ·  Dana-Farber Cancer Institute (2)  ·  ADC Therapeutics S.A. (1)  ·  Asha Nayak (1)  ·  Calluna Pharma AS (1)  ·  Fondazione Italiana Linfomi - ETS (1)  ·  Fred Hutchinson Cancer Center (1)  ·  French Innovative Leukemia Organisation (1)  ·  German CLL Study Group (1)  ·  John Mark Sloan (1)  ·  Mayo Clinic (1)  ·  MorphoSys AG (1)  ·  Nordic Lymphoma Group (1)  ·  OHSU Knight Cancer Institute (1)  ·  Oslo University Hospital (1)

Countries

United States (19)  ·  Italy (6)  ·  France (5)  ·  United Kingdom (5)  ·  Germany (4)  ·  Poland (4)  ·  Spain (4)  ·  Denmark (3)  ·  Austria (2)  ·  Belgium (2)  ·  Hungary (2)  ·  Norway (2)  ·  Romania (2)  ·  Australia (1)  ·  Czechia (1)

Top investigators

Anke Muth (1)  ·  Jean Yared, MD (1)  ·  Jennifer Brown, MD, PhD (1)  ·  Jorge J. Castillo, MD (1)  ·  Langdon Miller, MD (1)  ·  Lyndah Dreiling, MD (1)  ·  Marc Loriaux (1)  ·  Mats Jerkeman (1)  ·  Mohamed Sorror (1)  ·  Paula Cramer, Dr. med. (1)  ·  Pierluigi Zinzani, Prof. (1)  ·  Tormod K Guren, MDPhD (1)

Results publications

PMID 26472751, PMID 24450858, PMID 24615776, PMID 24615777, PMID 24615778, PMID 26968534, PMID 27247136, PMID 28327905, PMID 28424162, PMID 29296805, PMID 30967392, PMID 31723767, PMID 33297794, PMID 33516721, PMID 33961019, PMID 34414843, PMID 38620092, PMID 39499299, PMID 41124966

NIH funding

2014 (1), 2015 (1), P01CA018029 (1), P30CA015704 (1), P50CA097274 (1), R21CA159265 (1)